sellhighdrinklow, afrezzauser made me aware that an A1c kit like you reference is available at Walmart for $20. It offers two tests for that price. It lets a person do a test/check without making such an initial monetary commitment. I checked at Walmart the next time I went there, and it was there.
lakers_w, In paragraph 7 is that temporarily James S Shannon, or are those positions people Shannon will help MNKD recruit?
adambarlam, If the Imitrex is $21/pill, how much does the nasal spray cost? I will assume it is good for more than one spray. Is the Imitrex nasal spray a generic?
lakers_w, Is Shannon 59 years old? Is he also future CEO material at MNKD?
warren06, Excellent. That is what is needed. I don't know why Matt did not answer the question more specifically (including a lot of other things).
audiomr, I listened to the call twice. I read the SA transcript tonight. The part about expensing the insulin they did buy once upon a time makes me think it's Pfizer.
jmkopp, I am quoting directly from the transcript: Matt said, "But for example, it’s well known that we have a lot of insulin in inventory and we did buy that once upon a time, but we expensed it when we did to the extent we now use that in manufacturing of our products. We can charge Sanofi for what it cost us originally so we kind of recoup it now and it shows up as margin. So we have an accounting margin."
It appears MNKD is using the insulin it purchased from PFE long ago -- to answer your question.
Has anyone been able to read the paper presented at the Endo convention after this abstract was published? Was a paper available in the proceedings book of the convention?
failupward2, you either do not read the news, or you don't understand the news. It could be both.
factspls88, it's news this time that is substantive of trial data that documents Afrezza has less hypos than Novolog.
boyingtonevil, It is the American Association of Clinical Endocrinologists, AACE. It is in Nashville, and it is going on now. Dates are May 13 through May 17. The paper may already have been presented or at a poster session, etc. I don't know those details. I am not there, and I do not have a book of the proceedings and papers.
uvula2, get up from whacking your uvula and look up post hoc. That was started and done after FDA approval of Afrezza. The conclusion means Afrezza causes lots fewer hypoglycemia than Novolog (that it was compared against).
keyileo, It is a new 24 week study started and completed after the FDA approved Afrezza in June 2014. How could you misinterpret that! It was done by Sanofi with the idea of label improvement for Afrezza. That is what will happen with this new information that Afrezza generates far fewer hypos than Novolog.
im_typeone, you are in Afrezzauser's time in range group on his blog too with your results in addition to your twitter account.
mann_believer, if you are keeping up so well, how could you make such an egregious mistake in your preface to your label question in which you state "15 minutes prior to meal?"
stamas5, I am going to assume you are a type 2 with that a1c (6.6) and none of the symptoms of a type 1 that is in a honeymoon phase. You appear to be both insulin naïve, and you have never taken any oral drugs for diabetes. If you read or watch some Al Mann videos, he would call you an ideal candidate for Afrezza at meal times. If you are a type 2, you are one of the people Sanofi will be marketing Afrezza to in their promotions.
kevinmik, I found it. It is from WDBJ in Virginia about Dr. Bailey. Good to see.
kevinmik, where can I find the endo video you reference? What should I google to find it. Thanks.